Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 01 Oct 2024
Rollout of new medicines across New Zealand begins
1 October 2024 - Today marks the first day a range of new medicines, including cancer medicines, will start to ...
Posted by Michael Wonder on 01 Oct 2024
New Zealand Pharmaceutical Schedule - 1 October 2024
1 October 2024 - The October 2024 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 30 Sep 2024
Fresenius Kabi and Formycon receive US FDA approval for biosimilar Otulfi (ustekinumab-aauz)
30 September 2024 - In accordance with the patent settlement between Fresenius Kabi, Formycon and Johnson & Johnson, Fresenius Kabi has ...
Posted by Michael Wonder on 30 Sep 2024
Medicare Advantage and Medicare prescription drug programs to remain stable as CMS implements improvements to the programs in 2025
27 September 2024 - Today, the CMS announced that average premiums, benefits, and plan choices for Medicare Advantage and the Medicare ...
Posted by Michael Wonder on 30 Sep 2024
FDA approves imaging drug for evaluation of myocardial ischaemia and infarction
27 September 2024 - The US FDA has approved Flyrcado (flurpiridaz F 18) in adult patients with known or suspected coronary ...
Posted by Michael Wonder on 30 Sep 2024
Cost barriers to medication access in Australia: an analysis of the Patient Experience Survey in context
30 September 2024 - In November 2023, the Australian Bureau of Statistics released its 2022–23 Patient Experience Survey data. ...
Posted by Michael Wonder on 29 Sep 2024
Cabotegravir for the prevention of HIV-1 infection in adults and adolescents
26 September 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 29 Sep 2024
Enterprise Therapeutics granted rare paediatric disease designation in the US for novel cystic fibrosis investigational therapy ETD001
26 September 2024 - ETD001 is a novel, first in class blocker of the epithelial sodium channel aimed at treating people ...
Posted by Michael Wonder on 29 Sep 2024
Dupixent (dupilumab) approved in the US as the first ever biologic medicine for patients with COPD
27 September 2024 - Following recent approvals in the EU and China, the US approval is based on two landmark Phase ...
Posted by Michael Wonder on 29 Sep 2024
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
27 September 2024 - Today, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly) for adult and paediatric patients ...
Posted by Michael Wonder on 29 Sep 2024
Vertex announces Health Canada acceptance of new drug submission for vanzacaftor/tezacaftor/deutivacaftor, a next in class triple combination treatment for cystic fibrosis
26 September 2024 - Vertex Pharmaceuticals today announced that Health Canada has accepted for review its new drug submission for ...
Posted by Michael Wonder on 29 Sep 2024
AbbVie submits biologics license application to the FDA for telisotuzumab vedotin in previously treated non-small cell lung cancer
27 September 2024 - Biologics license application submission for accelerated approval is supported by data from the Phase 2 LUMINOSITY trial ...
Posted by Michael Wonder on 28 Sep 2024
Bayer submits supplemental new drug application to US FDA seeking expanded indication for Nubeqa (darolutamide) in metastatic hormone-sensitive prostate cancer
26 September 2024 - Submission is based on positive results from the investigational pivotal Phase 3 ARANOTE trial that showed Nubeqa ...
Posted by Michael Wonder on 28 Sep 2024
MHRA approves first medicine for rare immune disease APDS
27 September 2024 - The MHRA has on 25 September approved leniolisib phosphate (Joenja) to treat a rare immune disease known ...
Posted by Michael Wonder on 28 Sep 2024
Dupixent (dupilumab) approved in China as the first ever biologic medicine for patients with chronic obstructive pulmonary disease
27 September 2024 - Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based ...